Northwestern Mutual Wealth Management
LCTX icon

Northwestern Mutual Wealth Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16K Hold
887
– – ﹤0.01% 3763
2026
Q1 		$1.4K Hold
887
– – ﹤0.01% 3684
2025
Q4 		$1.48K Sell
887
-1
-0.1% -$2 ﹤0.01% 3558
2025
Q3 		$1.5K Buy
+888
New +$1.05K ﹤0.01% 3457
2024
Q1 		– Sell
-20
Closed -$22 – 3700
2023
Q4 		$22 Buy
+20
New +$22 ﹤0.01% 3426

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Northwestern Mutual Wealth Management's LCTX Position: Q2 2026 in Review

Northwestern Mutual Wealth Management held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 887 shares worth $1.16K. The position accounts for ﹤0.01% of the portfolio, ranked #3763.

Northwestern Mutual Wealth Management first reported a position in LCTX in Q4 2023 and has held it in 5 quarters since. The position peaked at $1.5K in Q3 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Northwestern Mutual Wealth Management held 887 shares of Lineage Cell Therapeutics worth $1.16K as of Q2 2026.
  • Northwestern Mutual Wealth Management left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Northwestern Mutual Wealth Management's portfolio in Q2 2026, its #3763 holding.
  • Northwestern Mutual Wealth Management first reported a position in Lineage Cell Therapeutics in Q4 2023 and has held it in 5 quarters since.
  • Northwestern Mutual Wealth Management's Lineage Cell Therapeutics position peaked at $1.5K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Northwestern Mutual Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.